derefr 3 hours ago
I had been looking into orexin agonists (along with other things like H3 autoreceptor antagonists) back when they were just a concept. It’s good to see them finally reaching commercialization. Although they’re not approved by our own (Canadian) regulatory body quite yet.
Now that they’re approved in the US, though, I’m looking very much forward to seeing how these drugs perform in off-label-ish treatment of the various other sleep disorders that I’m sure clinicians will now begin throwing them at.
SoupBread 3 hours ago
Anon84 5 hours ago
fedpost 3 hours ago
wewewedxfgdf 3 hours ago
WalterGR 3 hours ago
fennec-posix 5 hours ago
fishfasell 3 hours ago
almost_usual 3 hours ago
madhacker 3 hours ago
copperx 5 hours ago
EA-3167 4 hours ago
kbrannigan 3 hours ago
We have our NeuroLinkBrain Implant plugin to AI agent , so that you can vibe code 24/7 . To maximize shareholder value.
ValdikSS 4 hours ago
livinglist 3 hours ago
blinkbat 2 hours ago
stego-tech 2 hours ago
Here’s the thing: what a lot of these drugs are doing are basically acting as equivalents to the store-bought neurotransmitters you’d find in things like SSRIs or -phetamines/stimulants. To people lacking in these substances, they’re game changers.
The problem right now is a mismatch between regulation, availability, and testing regimes. Regulations are meant to prevent dystopian shit like employers mandating (or encouraging) a drug regimen for employment through threat of punitive fines or prosecution, while the private insurance markets promote unaffordability domestically (as North America is where over half of pharma revenues come from) and testing regimes fail to identify who is best suited for a given drug. All three of these prongs will shake out in time, but cause new problems as a result.
Where we’re at right now is less of a click-baity headline from The Economist, and more at the start of a new frontier in medicine that capitalizes on decades of research. We’ve maximized the benefits of “low-hanging” chemical-based drugs, and have moved into more complex, nuanced, or targeted drugs developed through modern compute rather than traditional drug trials alone. Things will change very quickly, and then stagnate again when we’ve picked clean the easy fruits from these new branches.
acosmism 4 hours ago
steele 4 hours ago